Kadcyla (Trastuzumab emtansine)

Kadcyla (trastuzumab emtansine) is a targeted cancer therapy used primarily for HER2-positive breast cancer. It combines two components: trastuzumab, which specifically attaches to HER2 proteins on cancer cells, and DM1, a potent chemotherapy agent. When administered, Kadcyla directs the chemotherapy directly to the HER2-positive cancer cells, delivering the treatment where it’s needed most while minimizing effects on healthy tissue. This targeted approach helps to slow or shrink tumor growth and can be used when cancer has spread or after surgery to reduce recurrence risk.